Filtered By:
Condition: Stroke
Drug: Actos

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
Conclusions Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. However, the risks of heart failure, bone fracture, oedema and weight gain were increased.
Source: BMJ Open - January 4, 2017 Category: Journals (General) Authors: Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., Ovbiagele, B. Tags: Open access, Cardiovascular medicine, Diabetes and Endocrinology Research Source Type: research

Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial - Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN.
CONTEXT: Pioglitazone reduces cardiovascular risk in non-diabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture. OBJECTIVE: To characterize fractures associated with pio...
Source: SafetyLit - December 17, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial.
CONCLUSIONS: Fractures affected 8.8% of placebo-treated patients within five years after an ischemic stroke or TIA. Pioglitazone increased the absolute fracture risk by 1.6%-4.9% and the relative risk by 47-60%, depending on fracture classification. Our analysis suggests that treatments to improve bone health and prevent falls may help optimize the risk/benefit ratio for pioglitazone. PMID: 27935736 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - December 8, 2016 Category: Endocrinology Authors: Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, IRIS Trial Investigators Tags: J Clin Endocrinol Metab Source Type: research

Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.
CONCLUSION: The promising data from experimental studies regarding cardioprotective gliptin-associated effects against stroke were not supported by available data from trials specifically looking at cardiovascular safety. PMID: 27916514 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - November 30, 2016 Category: Endocrinology Authors: Barkas F, Elisaf M, Tsimihodimos V, Milionis H Tags: Diabetes Metab Source Type: research

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
CONCLUSIONS Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
Source: Diabetes Care - September 21, 2016 Category: Endocrinology Authors: Inzucchi, S. E.; Viscoli, C. M.; Young, L. H.; Furie, K. L.; Gorman, M.; Lovejoy, A. M.; Dagogo-Jack, S.; Ismail-Beigi, F.; Korytkowski, M. T.; Pratley, R. E.; Schwartz, G. G.; Kernan, W. N.; for the IRIS Trial Investigators Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research

Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 17, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
New England Journal of Medicine,Volume 375, Issue 7, Page 702-704, August 2016.
Source: New England Journal of Medicine - August 16, 2016 Category: Internal Medicine Source Type: research

Pioglitazone After Stroke or TIA Reduces Stroke and MI, But Also Has Significant Harms.
PMID: 27548603 [PubMed - as supplied by publisher]
Source: American Family Physician - August 14, 2016 Category: Primary Care Authors: Ebell MH Tags: Am Fam Physician Source Type: research

Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning? Emerging Therapy Critiques
Source: Stroke - June 26, 2016 Category: Neurology Authors: Ntaios, G., Kent, T. A. Tags: Diabetes, Type 2 Emerging Therapy Critiques Source Type: research

Pioglitazone After Ischemic Stroke or Transient Ischemic Attack
In patients without diabetes but who have insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among those patients who received pioglitazone than among those who received placebo.
Source: Journal of Vascular Surgery - June 24, 2016 Category: Surgery Authors: W.N. Kernan, C.M. Viscoli, K.L. Furie Tags: Abstract Source Type: research

Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Actos After Stroke May Prevent Diabetes (CME/CE)
(MedPage Today) -- Treatment appears to stop progression from pre-diabetes
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news